{{Rsnum
|rsid=2134142
|Gene=KSR2
|Chromosome=12
|position=117518703
|Orientation=minus
|GMAF=0.4302
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=KSR2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 23.9 | 56.6 | 19.5
| HCB | 29.9 | 59.1 | 10.9
| JPT | 35.4 | 49.6 | 15.0
| YRI | 44.2 | 42.2 | 13.6
| ASW | 21.1 | 52.6 | 26.3
| CHB | 29.9 | 59.1 | 10.9
| CHD | 37.6 | 48.6 | 13.8
| GIH | 12.9 | 44.6 | 42.6
| LWK | 33.6 | 49.1 | 17.3
| MEX | 31.0 | 50.0 | 19.0
| MKK | 38.5 | 50.0 | 11.5
| TSI | 31.4 | 50.0 | 18.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2134142
|Name_s=
|Gene_s=KSR2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00001. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109343
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2134142
|overall_frequency_n=56
|overall_frequency_d=128
|overall_frequency=0.4375
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=45
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}